You are here

Article Text

Article menu
Download PDFPDF
Letter
Cyclic intravenous pamidronate treatment in children with nodulosis, arthropathy and osteolysis syndrome
  1. S M Al-Mayouf1,
  2. S M Madi2,
  3. B S Bin-Abbas3
  1. 1Department of Pediatrics, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
  2. 2Department of physiotherapy, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
  3. 3Department of Pediatrics, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
  1. Correspondence to:
    S M Al-Mayouf
    Department of Pediatrics, King Faisal Specialist Hospital and Research Center, PO Box 3354 (MBC-58), Riyadh 11211, Saudi Arabia; mayouf{at}kfshrc.edu.sa

https://doi.org/10.1136/ard.2005.035725

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Nodulosis, arthropathy and osteolysis (NAO) syndrome is a rare autosomal recessive multicenteric osteolysis.1,2 Few therapeutic studies have proved the efficacy of pamidronate in children with genetic osteoporotic syndrome such as osteogensis imperfecta.3,4

    Therefore, we conducted an uncontrolled prospective study to assess the effect of cyclic intravenous pamidronate treatment on the clinical course of NAO syndrome in children and its effect on bone mineral density.

    Seven children with NAO syndrome aged 5–14 years were treated with intravenous pamidronate between June 2003 and July 2004. The treatment was given after informed consent was obtained from the parents.

    Pamidronate was diluted in 250 ml of isotonic saline and infused …

    View Full Text

    Footnotes

    • Competing interests: None declared.